Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis

Fig. 4

Subgroup analysis of clinical accuracy for different ctDNA detection methods. The ctDNA detection at the first posttreatment time point (ctDNA MRD landmark) or longitudinal monitoring posttreatment (ctDNA surveillance) for non-small cell lung cancer were indicated by different icons of different colors. Error bars, binomial 95% confidence intervals. Each icon represents a summary of the results of studies using a specific detection method under different monitoring methods. L refers to landmark while S refers to surveillance

Back to article page